Currently, CAR-T cell therapies only work in blood cancers, the minor part of the cancer therapies market. “The addition of these three new facilities and the expanded CRADA with our research collaborators at the NCI will help us bring cell therapies to more people with cancer around the world,” said Alessandro Riva, MD, Gilead’s Executive Vice President, Oncology Therapeutics & Head, Cell Therapy.īoth, Kite and Novartis have still to proove that autologous CAR-T cell therapies can spend significant amounts of money as manufacturing is extraordinarily costly, lengthy, and complex, which affects treatment prices, and need to become more reproducible. The Maryland site will support the work of a new Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop adoptive cell therapies targeting patient-specific tumour neoantigens. that will be used for cell therapy research, development and the expansion of clinical manufacturing capabilities, and has leased a 26,000 square-foot facility in Gaithersburg, Maryland. Connect Niamh Proctor County Donegal, Ireland. Cell Therapy Specialist at Kite Pharma The Hague. In addition to the Netherlands facility, Kite has recently purchased a new building in Santa Monica from Astellas Pharma Inc. Amsterdam, North Holland, Netherlands Cell Therapy Specialist Kite Pharma Dec 2021 - Dec 2022 1 year 1 month. “This new European manufacturing facility will enable personalised cell therapies to be manufactured in closer geographic proximity to the patients who will receive them, potentially shortening the turnaround time for people who urgently need care,” said John Milligan, PhD, Gilead’s President and CEO. The lease of the Dutch site near the airport is not only part of EU commercialisation but of Kite's global roll out of the second approved autologous CAR-T cell therapy ever, which followed the approval of Novartis Kymriah (tisagenlecleucel) in 2017. Kite's CD19-targeting CAR-T cell therapy axicabtagene ciloleucel, which received FDA approval in October 2017 to treat B cell lymphomas under the brand name Yescarta, is currently under rewiew by the European Medicines Agency (EMA).

Kite pharma amsterdam